CSIMarket Company Name, Ticker, Suppliers, else..
 
Sage Therapeutics Inc   (SAGE)
Other Ticker:  
 
 
Price: $6.8100 $0.22 3.338%
Day's High: $6.82 Week Perf: 5.91 %
Day's Low: $ 6.50 30 Day Perf: -13.03 %
Volume (M): 762 52 Wk High: $ 28.26
Volume (M$): $ 5,187 52 Wk Avg: $15.59
Open: $6.57 52 Wk Low: $5.84



 Market Capitalization (Millions $) 408
 Shares Outstanding (Millions) 60
 Employees -
 Revenues (TTM) (Millions $) 11
 Net Income (TTM) (Millions $) -656
 Cash Flow (TTM) (Millions $) -51
 Capital Exp. (TTM) (Millions $) 1

Sage Therapeutics Inc
Sage Therapeutics Inc is a biopharmaceutical company that develops and commercializes novel medicines for the treatment of central nervous system disorders. The company focuses on developing drugs that target the GABA pathway, which is involved in regulating the activity of neurons in the brain. Sage Therapeutics is known for its research in developing treatments for conditions such as postpartum depression, major depressive disorder, and movement disorders. The company is headquartered in Cambridge, Massachusetts, and is committed to improving the lives of individuals suffering from these debilitating disorders.


   Company Address: 215 First Street Cambridge 2142 MA
   Company Phone Number: 299-8380   Stock Exchange / Ticker: NASDAQ SAGE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Navigating the Challenges of Alzheimers and Essential Tremor The Journey of Sage Therapeutics Amid Mixed Clinical Ou...

Published Tue, Oct 8 2024 11:47 AM UTC

'Abstract' Sage Therapeutics, Inc. has recently reported findings from two pivotal clinical studies evaluating newer treatments for neurological conditions, particularly Alzheimer's disease and essential tremor. This article interprets the topline results from the LIGHTWAVE study for dalzanemdor (SAGE-718) regarding mild cognitive impairment and mild dementia in Alzheimer's...
Business Update

Discontinuation of SAGE-324 Development Following Negative Phase 2 Results Implications for Essential Tremor Treatment

Published Thu, Sep 26 2024 11:47 AM UTC

Sage Therapeutics, Inc. has announced the cessation of its collaboration with Biogen regarding the SAGE-324 program, a move that follows the recent unfavorable outcomes of the Phase 2 KINETIC 2 Study. This decision marks a significant turn in the investigational treatment landscape for essential tremor (ET), as SAGE-324 was one of the promising candidates being explored for ...
Announcement

Rosen Law Firm Calls on Sage Therapeutics Investors Last Chance to Join Class Action Before October 28 Dead...

Published Tue, Sep 17 2024 4:05 PM UTC

'Rosen Law Firm Urges Sage Therapeutics, Inc. Investors to Act Before Securities Class Action Deadline'In a significant reminder for investors, Rosen Law Firm, a prominent and trusted global investor rights law firm, has announced the urging of Sage Therapeutics, Inc. (NASDAQ: SAGE) shareholders to secure counsel concerning an impending important deadline linked to a securit...
Business Update

Navigating New Frontiers in Brain Health Sage Therapeutics Promising Journey with ZURZUVAE

Published Thu, Aug 1 2024 6:28 AM UTC

Sage Therapeutics: Advancing Brain Health Through Innovative Therapies and Strong Market Performance'Abstract' Sage Therapeutics, Inc. is at the forefront of transforming brain health through pioneering biopharmaceuticals targeting serious mood disorders, particularly postpartum depression (PPD). This article examines their recent achievements, focusing on the promising co...
Business Update

Evaluating the Phase 2 Results of SAGE-324 (BIIB124) for Essential Tremor Treatment A Disappointing Outcome for Sage ...

Published Wed, Jul 24 2024 1:47 PM UTC

In a collaborative effort, Sage Therapeutics, Inc. and Biogen Inc. have recently disclosed the topline findings from the Phase 2 KINETIC 2 study evaluating the potential effectiveness of SAGE-324 (BIIB124) as a treatment for essential tremor (ET). This article aims to outline the key facts derived from this study and assess the impact these results may have on both pharmaceu...






Sage Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com